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7Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyThe template of hepatitis B virus (HBV) transcription, the covalently closed circular DNA (cccDNA), plays a key role in
the life cycle of the virus and permits the persistence of infection. Novel molecular techniques have opened new possibilities
to investigate the organization and the activity of the cccDNA minichromosome in vivo, and recent advances have started
to shed light on the complexity of the mechanisms controlling cccDNA function. Nuclear cccDNA accumulates in hepa-
tocyte nuclei as a stable minichromosome organized by histone and non-histone viral and cellular proteins. Identiﬁcation of
the molecular mechanisms regulating cccDNA stability and its transcriptional activity at the RNA, DNA and epigenetic
levels in the course of chronic hepatitis B (CH-B) infection may reveal new potential therapeutic targets for anti-HBV
drugs and hence assist in the design of strategies aimed at silencing and eventually depleting the cccDNA reservoir.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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hIP, chromatin immuno-precipitation.infecting primates, rodents, and birds. One common
characteristic of these viruses is their high species and
cell-type speciﬁcity, as well as a unique genomic organi-
zation and replication mechanism.1. cccDNA and HBV replication
Upon infection of the hepatocyte, the core nucleo-
capsid is released into the cytoplasm and the genomic
DNA is transferred to the cell nucleus, where the
relaxed circular (RC), partially double-stranded DNA
is converted into a covalently closed circular DNA
(cccDNA) molecule [2,3] (Fig. 1). Biochemically, the
formation of cccDNA from RC DNA requires: (a)
the removal of the viral polymerase covalently attached
to the 50 end of the negative DNA strand; (b) the
removal from the 50 end of the plus-strand DNA of
the short RNA oligomer which is used to prime thePublished by Elsevier B.V. All rights reserved.
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Fig. 1. HBV cccDNA in the viral life-cycle.
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one copy of the short terminal redundancy (‘‘r”) from
the minus-strand DNA; (d) the completion of the posi-
tive strand, which is variable in length in the RC DNA,
by the cellular replicative machinery and (e) the ligation
of the two viral DNA strands (reviewed in [4]). In hep-
atoma cell replication systems, the HBV cccDNA
derives predominantly from RC DNA with a precise
junction sequence and is accompanied, diﬀerently from
DHBV replicating cells and human infected livers, by
the accumulation of the ‘‘protein-free or PF-RC DNA”
intermediates, from which the covalently attached viral
reverse transcriptase (RT) protein has been removed
[5]. PF-RC DNA, in contrast to RT-linked RC DNA
contains almost exclusively, mature plus-strand DNA,
suggesting that the RT protein is removed preferentially
from RC DNA in mature core particles [5]. A small
amount of cccDNA can also be generated from the
so-called double-stranded linear (DSL) form of HBV-
DNA [6] by intramolecular ligation of the linear
DNA ends via nonhomologous end joining [NHEJ]
[7]. However, this process of ‘‘illegitimate replication”
leads to the formation of a cccDNA that harbors small
deletions and/or insertions that preclude viral DNA
replication.Disguised as a stable non-integrated minichromo-
some, the cccDNA is not replicated by the host’s semi-
conservative DNA synthesis machinery, but it utilizes
the cellular transcriptional machinery to produce all
viral RNAs necessary for protein production and viral
replication, which takes place in the cytoplasm after
reverse transcription of the pregenomic RNA (pgRNA)
[8]. Of note, experiments performed using the duck
model revealed that the major source of cccDNA in
infected hepatocytes comes from newly synthesized
nucleocapsids, which are not enveloped and secreted
into the blood, but are transported into the nucleus to
ensure accumulation, and later maintenance of the
cccDNA pool [9,10]. Thus, these studies indicate that
multiple rounds of infection are not needed to establish
a stable cccDNA pool in infected cells. Evidence from
animal models indicated that 1 to 50 cccDNA molecules
accumulate per cell [3,11–13] and analysis of cccDNA
distribution at the single cell level revealed that cccDNA
amount varied signiﬁcantly from cell to cell in the course
of chronic infection in the duck model, where a fraction
of cells was found to contain only one cccDNA copy
[14]. However, the viral and host factors that control
cccDNA formation and cccDNA pool size are yet
poorly deﬁned. A negative-feedback mechanism might
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suppressing cccDNA ampliﬁcation [15,16]: when nuclear
cccDNA levels reach 10–50 copies suﬃcient LS protein
is made to shut oﬀ eﬃciently the cccDNA ampliﬁcation
pathway and redirect mature nucleocapsids (containing
RC DNA) to envelopment and extracellular secretion.2. Control of cccDNA pool in hepadnavirus infection
cccDNA is very stable in quiescent hepatocytes and
the size of cccDNA pool, once established, may be
reduced through diﬀerent mechanisms that entail cell
killing, dilution by cell proliferation and cell ‘‘cure”
mediated by inﬂammatory cytokines. More recently,
the possibility that the functionality of persisting
cccDNA might be controlled by a reduction of its tran-
scriptional activity has been proposed. Most of our
knowledge on cccDNA pool size control in infected liv-
ers comes from transient and chronic hepatitis B infec-
tion in the woodchuck model [17]. It has to be
emphasized, however, that diﬀerences may exist in both
cccDNA dynamics and the eﬃciency and mechanisms of
viral DNA integration into the host genome between
HBV and WHV. In general, cccDNA can persist
throughout the life span of the quiescent hepatocytes
without aﬀecting their viability. On the contrary, cell
division may favour dilution/loss of cccDNA during
mitosis, so that selection of cccDNA-free cells may
occur when cells are forced to divide to compensate
the loss of infected cells killed by the T cell response.
In the acute phase hepadnavirus infection can spread
to the entire hepatocyte population in the liver and,
the uninfected hepatocytes present in the recovered liver
have been shown to derive from previously infected
hepatocytes [17,18]. During virus clearance antiviral
cytokines are thought to block virus replication and
the formation of new cccDNA. Clearance of infected
hepatocytes from both replicative intermediates and
cccDNA would occur through three modalities. In the
ﬁrst scenario, cccDNA is primarily eliminated by cyto-
kines and cell death or cell proliferation do not contrib-
ute signiﬁcantly [the ‘‘cure” model]. In the second,
cytokines suppress cytoplasmic viral replication and
new cccDNA formation but do not act on pre-existing
cccDNA that is eliminated by both cell death and mito-
tic loss and would need a turnover of approximately 0.7
of the total liver mass [the ‘‘death and compensatory
proliferation” model]. In the third, cccDNA survives
hepatocytes mitosis, is distributed in a binomial fashion
to the progeny hepatocytes and it is eliminated only by
the elimination of infected cells, requiring an estimated
turnover exceeding 2.5 times the total liver mass [the
‘‘cell death” model] (reviewed in [17]). An elegant com-
puter modelling study based on the analysis of hepato-
cyte turnover during the resolution of untreated orentecavir-treated transiently infected woodchucks, indi-
cated that cccDNA clearance requires, in addition to cell
death, a combination of cytokine suppression and mito-
tic loss [19]. In chronically infected woodchuck livers,
the identiﬁcation of uninfected cell clones, which have
lost cccDNA, but still contain ‘‘traces” of the infection
in form of viral integrations has been explained as a
cccDNA clearance without cell destruction [20,21]. Since
liver cell death and regeneration usually occur in chron-
ically infected woodchuck livers, an alternative hypoth-
esis might be that surviving hepatocytes harbouring
both viral integrations and cccDNA may divide,
cccDNA would be lost through cell division while the
integrated DNA would persist in daughter cells
[20,21]. Thus, in chronic infection, killing of hepatocytes
may be instrumental not only to eliminate infected cells
but also to induce hepatocyte proliferation which, in
turn, may favour cccDNA loss. On the other hand, stud-
ies have shown that very low levels of cccDNA can per-
sist indeﬁnitely, possibly explaining life-long immune
responses to HBV despite clinical resolution of HBV
infection [22,23].
As HBV polymerase inhibitors do not directly aﬀect
the cccDNA, a decrease in cccDNA levels is supposed
to derive from the lack of suﬃcient recycling of viral
nucleocapsids to the nucleus, due to the strong inhibi-
tion of viral DNA synthesis in the cytoplasm, and less
incoming viruses from the blood. Following this sce-
nario, cccDNA depletion will require many years of
nucleos(t)ide drug administration and it is expected to
lead to the selection of resistant variants [24]. Impor-
tantly, currently available nucleos(t)ide analogs do not
prevent cccDNA formation when cells are exposed to
a new round of viral infection [25–27], which in turn
has important clinical implications in terms of treatment
duration as persisting viremia during the antiviral treat-
ment might be responsible for new rounds of infection.
Simultaneous treatment with antiviral agents acting
through diﬀerent mechanisms and, possibly, limiting
hepatocytes reinfection [28–31], as well as the develop-
ment of novel therapeutic strategies aimed at eradicating
cccDNA from the liver may be necessary to eventually
achieve clearance of infection.3. Structure of the cccDNA minichromosome
Nuclear hepadnaviral cccDNA molecules are orga-
nized into a chromatin-like structure as a viral minichro-
mosome that displays the typical beads-on-a string
arrangement at electron microscopy and reveals the
nucleosomal packaging of transcriptionally inactive
chromatin [3,32]. Organization of viral DNAs into a
nucleosomal structure has been described for the poly-
oma viruses [33], simian virus 40 (SV40) [34], human
(HPVs) [35] and bovine papilloma viruses (BPV) [36],
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[39] viruses. These viruses, with the possible exception
of Herpes simplex, all produce covalently closed dou-
ble-stranded DNAs (cccDNAs) that are found in the
nuclei of infected cells. Two populations of Hepadnavi-
ral minichromosomes, corresponding to a full or half
complement of nucleosomes, can be detected possibly
reﬂecting dynamic changes related to transcriptional
regulation [3]. HBV minichromosome has been shown
to consist of both histone and non-histone proteins
[40]. Histone proteins H3 and H2B were the most prom-
inent species but lower levels of histone proteins H4,
H2A, and H1 were also detectable by immunoblotting
on puriﬁed nuclear nucleocapsid complexes [40]. The
virally encoded core protein is a structural component
of the HBV minichromosome, binds preferentially to
HBV double-stranded DNA and its binding results in
a reduction of the nucleosomal spacing of the HBV
nucleoprotein complexes by 10% from 200 bp toHuh7 or HepG2 cells
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linear full-length HBV monomers
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sonicate
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Fig. 2. The cccDNA chromatin i180 bp [40]. A combination of in vitro approaches,
including classical oligonucleotide gel retardation
(EMSA) and DNAse protection assays, have shown that
a number of transcription factors bind in vitro to the
HBV enhancers 1 and 2 and regulate transcription dri-
ven by the same HBV regulatory elements [41] but their
association with the viral minicromosome has not been
proven in vivo. The chromatin immuno-precipitation
(ChIP) method is a powerful technique that allows the
identiﬁcation in vivo, at a resolution of a few hundred
base pairs, of the DNA binding sites of virtually any
chromosome component [42,43]. The principle relies
upon the ﬁxation of protein–DNA and protein–protein
interactions in vivo by the cross-linking agent formalde-
hyde. Chromatin is then disrupted by sonication, and
the cross-linked protein of interest immuno-precipitated
with speciﬁc antibody directed against histones, cova-
lently modiﬁed (acetylated, methylated, SUMOlated
etc.) histones, transcription factors, transcriptional co-liver tissue
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modiﬁed versions. After the cross-links are released by
heating the immuno-precipitated DNA is used as a tem-
plate in classic or real-time PCRs using oligonucleotides
that amplify the region presumably bound by the pro-
tein of interest. ChIP-based protocols have evolved over
time to work on as low as 1000 cultured cells as well as
on a variety of surgical and biopsy tissue samples. We
have recently developed a ChIP-based quantitative tech-
nique to study the recruitment in vivo of cellular and
viral proteins onto the HBV minichromosome [44]
(Fig. 2). The HBV cccDNA ChIP assay combines a
cccDNA ChIP step with a sensitive and speciﬁc real-
time PCR protocol for cccDNA quantiﬁcation [45].
The assay has been ﬁrst used to immunoprecipitate
and analyse the cccDNA in a cellular model of HBV
replication based upon the transient transfection of lin-
ear full-length HBV monomers into HuH7 and HepG2
hepatoma cells [46] and subsequently adapted to study
the cccDNA in baculovirus-HBV-infected cells [47],
hepatocytes derived from the livers of humanized chi-
mera mice infected in vivo with HBV (Dandri and Bello-
ni, unpublished observations) and liver biopsy samples
from chronic hepatitis B patients [44]. Using the
cccDNA-ChIP assay we and others have conﬁrmed the
recruitment in vivo of H3 and H4 histones [44,48] and
of HBV core proteins on the cccDNA minichromosome
[44]. Using the same approach several cellular transcrip-
tion factors, including CREB, ATF, STAT1 and
STAT2, and chromatin modifying enzymes have been
shown to bind to the cccDNA in cells replicating HBV
[49, Belloni, unpublished observations]. The demonstra-
tion that the cellular histone acetyltransferases CBP (a
coactivator of both CREB and ATF transcription fac-
tors), p300 and PCAF/GCN5 and the histone deacety-
lases HDAC1 and hSirtl are recruited with diﬀerent
kinetics onto the cccDNA in cells replicating HBV imply
that cccDNA bound histones may undergo regulatory
post-translational modiﬁcations.4. cccDNA quantiﬁcation and activity in HBV chronic
carriers
The development of highly selective real-time poly-
merase chain reaction (PCR) assays has provided new
sensitive tools to investigate the replicative activity
[50,51] and the eﬀectiveness of antiviral therapy
[28,30,45] in infected patients by enabling accurate
determination of serological and intrahepatic HBV-
DNA levels, including speciﬁc detection and quantiﬁca-
tion of the cccDNA in human liver biopsies. Studies
have shown that cccDNA loads vary signiﬁcantly in
the diﬀerent phases of CH-B infection and that patients
who underwent HBeAg seroconversion were more likely
to have lower cccDNA levels at the beginning of therapy[45]. The lower viremia generally observed in HBeAg-
negative patients appeared to be due not only to the
lower cccDNA content (>1 log) but also to reduced rep-
lication eﬃciency, which was deﬁned as the amount of
relaxed circular HBV DNA (rcDNA) produced per
cccDNA molecule [51]. Quantitative measurements of
HBV RNA transcripts also indicated that lower
steady-state levels of pgRNA found in HBeAg-negative
patients accounted for the reduced virion productivity
observed at the DNA level.
The good correlation observed between pgRNA and
rcDNA copy number indicated that impairment of rep-
licative activity in HBeAg-negative patients was not due
to diﬀerences in reverse transcription eﬃciency [50,51].
Surprisingly, impairment in virion productivity was
not linked to the presence of common PC/BCP variants,
since HBV replicative activity was mostly reduced in
HBeAg-negative patients without detectable PC/BCP
mutations [51]. Although viral titres correlated with
the amount of cccDNA present in the liver in HBeAg-
positive patients, there was poor correlation between
viremia and intrahepatic cccDNA amounts detected in
HBeAg-negative patients, implying that viral productiv-
ity can be speciﬁcally impaired in the low replicative
HBeAg-negative phase of chronic hepatitis B, and
strengthen the notion that viremia measurements in
HBeAg-negative patients are not good predictive mark-
ers of infection in the liver [28,51]. The ﬁnding that levels
of preS/S RNA transcripts and HBsAg concentrations
per cccDNA molecule did not diﬀer signiﬁcantly
between the two HBeAg groups, implied that only the
replicative pathway was speciﬁcally impaired in those
HBeAg-negative patients and hence, that the production
of viral and subviral particles may be diﬀerently regu-
lated in the course of HBV-chronic infection [51].
Nevertheless, the molecular mechanisms responsible
for the lower HBV replicative activity determined in
treatment naı¨ve HBeAg-negative patients remain to be
elucidated.5. Factors regulating cccDNA activity
Due to the narrow host range of HBV and limited
animal models available [52], knowledge of the factors
regulating the transcriptional activity of the cccDNA
in vivo is still very limited. These factors need to be elu-
cidated since they will aﬀect the size and ultimately the
stability of the cccDNA pool, and therefore, will inﬂu-
ence the clinical course of ongoing infection.
5.1. Immune-mediated factors
Experiments with HBV-replicating transgenic mice
and chimpanzees have shown that inﬂammatory cyto-
kines, such as type 1 interferon and TNF alpha, can eﬃ-
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immune-mediated mechanisms, which also contribute
to diminish the cccDNA reservoirs from infected cells
[53]. However, in the chronic phase these processes
may be ineﬀective, and in the absence of cell division,
the long half-life of the hepatocytes will guarantee
cccDNA survival in infected hepatocytes. Kupﬀer cells
and dendritic cells play a major role in mediating both
innate and adaptive immune responses and the molecu-
lar mechanisms by which the innate and adaptive
immune response can aﬀect viral replication are only
starting to emerge [53–56]. A growing body of evidence
indicates that several viruses evolved mechanisms to
directly suppress the host defence by altering diﬀerent
pathways of the innate immune response [57,58]. Nota-
bly, chronic hepatitis B infection has been associated
with a signiﬁcant reduction of dendritic cell functions
and impairment of the innate immune response [59].
Down-regulation of Toll-like receptor signaling was
recently demonstrated in the liver and blood of
HBeAg-positive chronic carriers, revealing the occur-
rence of potentially important interactions between viri-
ons, HBeAg and the innate immune response [56,60,
Dandri, unpublished observations].
5.2. Virological factors
The complex interplay between virus and host factors
occurring in the various phases of chronic infection is
likely to promote the selection of certain HBV variants.
A recent in vivo virological study [61] demonstrated
ongoing signiﬁcant accumulation of viral genetic diver-
sity in HBeAg seroconverters due to selective pressure
operated by the immune response. Transcription of
pregenomic RNA is under the control of the basal core
promoter (BCP) and mutations in this region and in the
precore (PC) region are common in HBeAg-negative
individuals and have been shown to aﬀect viral replica-
tion in vitro [62–64]. Occurrence of mutations within
the regulatory regions of the virus may also aﬀect
HBV replication activity in vivo. However, current
knowledge of the transcriptional state of diﬀerent
HBV isolates is mostly based on measurements per-
formed in vitro after transfection of the genomic HBV-
DNA inserted on a plasmid backbone. In these systems,
structure and organization of the cccDNA cannot be
recapitulated, and hence, the factors inﬂuencing the
transcriptional activity of the cccDNA need to be
assessed in vivo.
Recent studies have shown that in a minority of
HBeAg-negative patients only cccDNA molecules har-
bouring PC/BCP mutations were detected. These indi-
viduals displayed signiﬁcantly higher levels of
replicative activity (median 150 vs. 6 rcDNA/cccDNA)
and higher mutation frequency (0.46% vs. 0.18%;
p = 0.001) compared to HBeAg-negative patients with-out detectable PC/BCP mutations [65]. Of note, the
selection of BCP mutations was associated with higher
replication levels and worsening of clinical manifesta-
tions [51].
5.3. Epigenetic factors
Transcriptional regulation of gene expression rely on
nuclear enzymatic activities that constantly modify
chromatin to make it competent or refractory to gene
activation. The amino-terminal tails of the four core his-
tones on the nucleosome surface are subjected to a vari-
ety of enzyme-catalyzed, posttranslational modiﬁcations
of selected amino acids, including lysine acetylation,
lysine and arginine methylation, serine phosphorylation,
and attachment of the small peptides ubiquitin and
SUMO, that form a ‘‘histone code” specifying patterns
of gene expression. Histone acetylation has long been
associated with transcription initiation, whereas reduced
acetylation of histones H3 and H4 N-terminal tails is a
key signal for the subsequent recruitment of histone
methylases and DNA methylation enzymes that results
in chromatin based repression of gene expression and
hetero-chromatinization [66–68]. The principal histone
tails and DNA modiﬁcations and their functional
impact on transcription are outlined in Fig. 3. In all
eukaryotes protein coding genes transcribed by the Pol
II are under the control of short discrete DNA elements
arranged in promoters and enhancers. These sequences,
and their complex embricate juxtapositions, dictate the
binding of sequence-speciﬁc transcription factors (TFs)
to activate, or repress, transcription in a gene-speciﬁc
way. A common set of ‘‘general transcription farctors”
(GTFs) are involved in the activation of essentially all
genes. Among these, of primary importance is TBP
and the associated TAFs, forming the TFIID complex.
The accessibility of TFs to their target DNA sequences
is regulated by the activity of a number of non-DNA
binding coactivators, such as p300, CBP, PCAF/
GCN5, CARM1, that (a) almost invariably harbor
enzymatic activities to modify the histone tails in the
nucleosomes, (b) form large >1 MDa-complexes with
10 or more subunits (SAGA, TFTC, Ccr4-Not) and
(c) mediate the interplay between the gene speciﬁc fac-
tors and the general transcriptional machinery [66–68].
Since HBV cccDNA has a nucleosomal organization
in infected cells and it is the template for cellular poly-
merases to transcribe all viral mRNAs and the RNA
pregenome acetylation and deacetylation of cccDNA-
bound histones might regulate transcription of viral
chromatin and, by inference, viral replication. Using
an antiacetylated-H3 or -H4 cccDNA ChIP assay we
found that HBV replication is indeed regulated, both
in cell based replication systems [44,47] and in the liver
of HBV chronically infected patients [44] by the acetyla-
tion status of H3/H4 histones bound to the viral
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recruitment histone acetyltransferases (PCAF and
p300/CBP) parallels viral replication in vitro [44,48]
whereas histone deacetylase 1 (HDAC1) recruitment
onto the cccDNA correlate with low HBV replication
in vitro and with low viremia in vivo [44] (Fig. 4). The
importance of cccDNA histone epigenetic modiﬁcations
in the regulation of the viral transcription/replication
cycle is further conﬁrmed by the observation that abro-
gation of PCAF expression by speciﬁc siRNAs reduces
HBV replication and acetylation of cccDNA bound his-
tones whereas the class I and class III histone deacety-
lases inhibitors trichostatin (TSA), valproate (VPA)
and nicotinamide (NAM) induce an evident increase
of both cccDNA-bound acetylated H4 and HBV repli-
cation [44,49]. Interestingly, valproate, that is used clin-
ically as an anticonvulsant and more recently in the
treatment of bipolar syndromes, has been shown to also
increase BPV, CMV and HIV viral replication in vitro,
to reactivate lytic replication of latent HHV8 in primary
eﬀusion lymphoma (PEL) cells [69] and FDA has
recently raised a warning for the use of the drug inCMV or HIV infected patients. Although VPA has been
frequently associated with hepatoxicity and severe acute
hepatis this has been mainly attributed to a direct mito-
chondrial toxicity and the possible interaction with a co-
existing HBV infection has not been assessed. By cou-
pling cccDNA quantiﬁcation and the cccDNA ChIP
assay we also found that HBV genotype (A vs. D) has
no eﬀect on the accumulation of cccDNA whereas the
YMDD mutant displays a reduced cccDNA accumula-
tion [44]. Interestingly, the acetylation of cccDNA-
bound H4 histone is not aﬀected either by the HBV
genotype or by the presence of the YMDD mutation,
suggesting that the YMDD mutant has a defect in
cccDNA molecules accumulation but the cccDNA itself
is then properly assembled as a minichromosome [44]. In
addition, we conﬁrmed that anti-polymerase drugs,
notably lamivudine and adefovir, do not have a notice-
able eﬀect on the accumulation of cccDNA (cccDNA
molecules per cell) and on the acetylation of cccDNA-
bound histone acetylation [44]. On the contrary, in
response to IFNa HDAC1 is actively recruited onto
the HBV minichromosone and cccDNA-bound histone
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Fig. 4. Schematic representation of cccDNA-bound histones acetylation status and the recruitment of chromatin modifying enzymes onto the viral
minichromosome in relation to viral replication and infection phase [40,44,49,70].
588 M. Levrero et al. / Journal of Hepatology 51 (2009) 581–592acetylation sharply decreases, without observing, in
these short-term cell culture-based experiments, signiﬁ-
cant changes in the levels of cccDNA [70]. These obser-
vations suggest that the ability of class I interferon to
inhibit HBV replication may be mediated, in addition
to the known post-translational mechanisms and degra-
dation of HBV transcripts [71,72], also by the epigenetic
modulation of the cccDNA function. We have also
shown that the HBx regulatory protein produced in
HBV replicating cells is recruited onto the cccDNA
minichromosome. HBV mutants that do not express
HBx are impaired in their replication and that exoge-
nously expressed HBx trans-complements the replica-
tion defects [49,73]. The kinetics of HBx recruitment
on the cccDNA parallels HBV replication and is similar
to that of the PCAF/GCN5 acetyltransferase [49].
Despite this observation and the physical interaction
between the two proteins, we could not ﬁnd any signif-
icant change in the recruitment of PCAF on the
cccDNA in cells replicating the HBx defective virus.
Instead, we found that cccDNA-bound histones are
more rapidly hypo-acetylated in cells replicating the
HBx mutant and the recruitment of the p300 acetyl-
transferase is severely impaired whereas the recruitment
of the histone deacetylases hSirtl and HDAC1 is
increased (Fig. 4) and occurs earlier. Accordingly, we
show that in cells replicating the HBx mutant the pool
of cccDNA is not reduced but the HBx mutant cccDNA
transcribes signiﬁcantly less pgRNA [49].In addition to post-translational modiﬁcations of his-
tones DNA methylation of CpG islands also contribute
to regulate gene expression. In silico analysis of HBV
genotype A identiﬁes two CpG islands in proximity to
the HBV surface gene start codon (island 1) and to the
enhancer 1/X gene promoter region (island 2) [74].
The HBV-DNA extracted from circulating virions does
not display signiﬁcant methylation whereas the HBV
CpG islands are methylated in transfected HepG2 cells
and in about 50% of HBV-infected liver tissues [74].
Although this study does not speciﬁcally analyze the
HBV cccDNA methylation status it shows that HBV-
DNA can be methylated in human tissues and thus
DNA methylation may also play a role in the regulation
of HBV gene expression.6. cccDNA is ‘‘suppressed’’ in occult hepatitis B
Stability and long-lasting persistence of HBV
cccDNA in the nuclei of hepatocytes represent the
molecular basis of occult hepatitis B infection (OBI), a
form of HBV infection characterized by the persistence
of HBV-DNA in the liver (and in some cases also in
the serum) of individuals who test negative for the
HBV surface antigen (HBsAg) [74]. On the basis of the
HBV antibody proﬁle, OBI has been distinguished in
seropositive-occult hepatitis B (when anti-HBc and/or
anti-HBs are present) and seronegative OBI (when anti-
M. Levrero et al. / Journal of Hepatology 51 (2009) 581–592 589HBc and anti-HBs are absent) [75]. In a small number of
these individuals, failure to detect HBsAg and occult
infection are due to HBV variants either producing an
antigenically modiﬁed HBsAg that is not recognized
by commercially available detection assays, or carrying
mutations in the HBV regulatory regions or in the Pol
gene responsible for defective protein synthesis and/or
replication activity [76–79]. Extensive molecular analy-
ses of entire viral genomes have revealed that occult
HBV populations have a large intra-individual genetic
heterogeneity that does not diﬀer from what is found
in HBsAg-positive subjects [80–82]. In most cases viral
genomic variability does not appear to play a fundamen-
tal role in inducing the occult HBV status and the
majority of occult HBV cases are infected with replica-
tion-competent HBVs displaying a strong suppression
of replication activity and gene expression with extre-
mely low levels of virion production [80,81]. In fact,
in vitro functional analysis showed that occult viral iso-
lates ‘‘re-acquire” normal capacities of replication, tran-
scription and protein synthesis once extrapolated from
the host’s liver microenvironment [81]. In addition, sev-
eral molecular virology studies have demonstrated the
presence of both HBV cccDNA molecules and viral
transcripts (including the viral pregenome) in the liver
of occult infected individuals who may have or may
not have HBV-DNA in the serum [81,83–85]. Real-time
PCR analysis has shown median intrahepatic HBV
cccDNA levels about 1 log lower than those observed
in HBeAg-negative chronic HBV carriers (0.002 cop-
ies/cell vs. 0.01 copies/cell) [45]. The persistence of such
minute amounts of cccDNA is consistent with the
hypothesis that the clinical resolution of HBV infection
does not occur through a complete eradication of the
virus from the liver and rather viral replication is con-
trolled by the host’s immune system. The presence of a
complete HBV replication cycle in HBsAg-negative
cases is conﬁrmed both by the demonstration of HBV-
speciﬁc T-cell responses in patients with occult HBV
infection, even when serum HBV markers were com-
pletely negative [86] and by the observations that occult
HBV can be transmitted through blood transfusion or
organ transplantation and occult HBV carriers are at
risk of HBV reactivation when exposed to immune sup-
pression (i.e. hematologic malignancies, HIV infection,
cancer chemotherapy, etc.) [87,88]. The molecular
mechanisms that keep viral replication under control
in seronegative occult infections have not been fully
deﬁned. Innate immune response and/or interference
by coinfecting agents (i.e. hepatitis C virus) may con-
tribute as additional factors negatively inﬂuencing
HBV replication and gene expression. However,
according to our ﬁndings on the important role played
by chromatin remodelling enzymes and the epigenetic
modulation of cccDNA function we have found that
the profound suppression of viral replication and viraltranscription in OBI livers gene associates with the
recruitment of several cellular several histone deacety-
lases and histone methylases onto the HBV minichro-
mosome (Pollicino, personal observations) (Fig. 4)
and with a speciﬁc pattern of HBV-DNA methylation
in occult infected patients [82].7. Conclusions
The availability of sensitive molecular assays for
direct cccDNA quantitation in liver tissues and the
development of new techniques based upon the analysis
of chromatin dynamics to study the regulation of
cccDNA function both in cellular models of HBV repli-
cation and in vivo has signiﬁcantly advanced our knowl-
edge of the molecular mechanisms regulating HBV
replication and persistence. One major conceptual
advance has been the recognition of the existence of a
complex network of epigenetic events that inﬂuence
both cccDNA function and HBV replication. Although
more work is needed to expand our knowledge, results
suggest that inactive carriers, anti-HBe positive patients
during low replication phases and patients with occult
HBV infection may share, although to a diﬀerent degree,
common mechanisms of active cccDNA suppression
mediated by epigenetic modiﬁcations of cccDNA and
cccDNA-bound histones. The feasibility to modulate
in a cell culture model cccDNA transcription using zinc
ﬁnger proteins (ZFPs) engineered to speciﬁcally bind
and repress the activity of the DHBV enhancer has been
recently reported [89]. Although attractive, in principle
this approach might be limited by the need for ZFPs
to be delivered using viral vectors or included in lipo-
somes or nanoparticles designed in order to target the
infected liver. The identiﬁcation of epigenetic marks of
active and inactive cccDNA and the precise deﬁnition
of the cellular enzymatic activities modulating transcrip-
tion of the cccDNA minichromosome, as well as the cel-
lular signaling pathways that modulate their activity,
opens new perspectives for the identiﬁcation of relevant
therapeutic targets to permanently suppress HBV tran-
scription/replication. On the other hand, we must con-
tinue our eﬀorts to understand the molecular basis of
cccDNA stability. Relevant issues would include: (a)
the identiﬁcation of the cellular proteins that are
involved in the conversion of RC DNA into the
cccDNA; (b) the identiﬁcation of proteins and pathways
aﬀecting the size of the nuclear HBV cccDNA pool in
diﬀerent categories of HBV patients; (c) the comparison
of naked vs. chromatinized cccDNA half-life to eluci-
date whether open/transcribed cccDNA would be less
stable compared to packed/inactive cccDNA. This
knowledge will hopefully allow us, in the long term, to
move a step forward from the control of HBV replica-
tion and disease to the cure of HBV infection.
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